Lumexa Imaging Holdings, Inc. (LMRI) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Lumexa Imaging Holdings, Inc. (LMRI) stock forecast summary
On Oct. 16, 2026, LMRI is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
Lumexa Imaging Holdings, Inc. is a small-cap company with a market capitalization of $1.04B. It ranks number 15 by market capitalization among the 29 Services-Medical Laboratories issuers in our coverage with a current forecast.
For LMRI, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -24.0%, measured on 49 forecast dates between 2026-05-12 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -49.0%, measured on 92 forecast dates between 2026-05-12 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LMRI included.
Follow LMRI freeLMRI price chart and AI forecast
How LMRI ranks among 5172 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Lumexa Imaging Holdings, Inc. (LMRI) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | LMRI | Rank |
|---|---|---|
| Market Cap | $1.04B | 15/29 |
| P/B Ratio | 1.68x | 15/22 |
| Book Value/Share | $6.40 | – |
Financial Health
| Metric | LMRI | Rank |
|---|---|---|
| Current Ratio | 1.44x | 21/26 |
| D/E Ratio | 1.94x | 5/22 |
| Financial Leverage | 2.94x | 5/22 |
| Interest Coverage | 1.4x | 5/23 |
| Working Capital | $78M | 15/26 |
Dividend & Shareholder Information
| Metric | LMRI | Rank |
|---|---|---|
| Shares Outstanding | 96M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $256M | 14.2% of assets |
| Cash & Short-term Investments | $70M | 3.9% of assets |
| Total Liabilities | $1.19B | 66.0% of assets |
| Short-term Debt | $151M | 8.4% of assets |
LMRI quarterly financials and insider trading
Lumexa Imaging Holdings, Inc. (LMRI) industry peers
Companies classified under the same SEC industry code as Lumexa Imaging Holdings, Inc. (Services-Medical Laboratories): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| LMRI Lumexa Imaging Holdings, Inc. | ▶ | $1.04B |
| NTRA Natera, Inc. | ▲ | $56.71B |
| DGX Quest Diagnostics Inc | ▼ | $25.94B |
| LH Labcorp Holdings Inc. | ▼ | $25.79B |
| GH Guardant Health, Inc. | ▲ | $21.28B |
| CAI Caris Life Sciences, Inc. | ▲ | $8.64B |
| RDNT Radnet, Inc. | ▶ | $5.41B |
| GRAL Grail, Inc. | ▲ | $5.26B |
| BLLN Billiontoone, Inc. | ▲ | $4.63B |
| VCYT Veracyte, Inc. | ▲ | $3.47B |
| CDNA Caredx, Inc. | ▲ | $3.31B |
| CELC Celcuity Inc. | ▲ | $2.77B |
| FTRE Fortrea Holdings Inc. | ▲ | $2.14B |
| PSNL Personalis, Inc. | ▲ | $1.67B |
| FRNM Freenome, Inc. | ▶ | $1.26B |
| CSTL Castle Biosciences Inc | ▲ | $976M |
| FLGT Fulgent Genetics, Inc. | ▲ | $545M |
| BDSX Biodesix Inc | ▲ | $250M |
| XGN Exagen Inc. | ▲ | $187M |
| BNR Burning Rock Biotech Ltd | ▲ | $139M |
| SERA Sera Prognostics, Inc. | ▼ | $80M |
| CFOR Capforce Inc. | ▲ | $43M |
| MDXH Mdxhealth Sa | ▲ | $20M |
| AMS American Shared Hospital Services | ▼ | $9M |
| ADVB Advanced Biomed Inc. | ▼ | $7M |
| ACON Aclarion, Inc. | ▲ | $5M |
| BGLC Bionexus Gene Lab Corp | ▲ | $4M |
| LUDG Ludwig Enterprises, Inc. | ▼ | $670K |
| FCHS First Choice Healthcare Solutions, Inc. | ▼ | $260K |
| RNLXY Renalytix Plc | ▶ | N/A |
Where LMRI sits on the market map
Lumexa Imaging Holdings, Inc. (LMRI) stock news
Loading...
Lumexa Imaging Holdings, Inc. (LMRI) stock forecast FAQ
What is the Lumexa Imaging Holdings, Inc. (LMRI) stock forecast?
On Oct. 16, 2026, LMRI is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Lumexa Imaging Holdings, Inc. stock predictions?
For LMRI, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -24.0%, measured on 49 forecast dates between 2026-05-12 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -49.0%, measured on 92 forecast dates between 2026-05-12 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Lumexa Imaging Holdings, Inc. forecasts updated?
Lumexa Imaging Holdings, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Lumexa Imaging Holdings, Inc.'s industry peers?
30 issuers in our coverage, LMRI included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Quest Diagnostics Inc (DGX), Labcorp Holdings Inc. (LH), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.